地舒单抗联合强化降尿酸治疗未改善痛风骨侵蚀CT评分
一项开放标签平行组先导随机对照试验纳入20例有足部骨侵蚀的痛风患者,比较地舒单抗(60 mg皮下每6个月)联合强化降尿酸治疗与单纯强化降尿酸治疗。尽管地舒单抗组血清CTX显著下降,但两组12个月时双足踝CT骨侵蚀评分均无变化,地舒单抗未提供额外获益。
要点
- 地舒单抗联合强化降尿酸治疗未改善痛风患者12个月CT骨侵蚀评分。
- 地舒单抗组血清CTX显著下降,但骨侵蚀评分与单纯强化降尿酸组无差异。
- 两组疼痛和功能等患者报告结局无差异,各发生一例严重不良事件(房颤/房扑)。
核心结论
- 在痛风骨侵蚀患者中,地舒单抗联合强化降尿酸治疗未较单纯强化降尿酸治疗提供额外获益。
研究设计与样本
- 开放标签、平行组先导随机对照试验,20例有至少一处确诊足部骨侵蚀的痛风患者按1:1分配。
- 干预组接受地舒单抗60 mg皮下每6个月联合强化降尿酸治疗(随机时血清尿酸≤5 mg/dL或300 µmol/L并维持),对照组仅强化降尿酸治疗。
- 主要结局为基线至12个月双足踝CT骨侵蚀评分变化,由对分组不知情的肌骨放射科医生评估。
主要发现
- 地舒单抗/强化降尿酸组血清CTX较单纯强化降尿酸组显著下降。
- 随访1年后,地舒单抗/强化降尿酸组和单纯强化降尿酸组的CT骨侵蚀评分均无区间变化。
- 其他次要结局两组间无差异。
- 严重不良事件共2例:地舒单抗/强化降尿酸组1例房颤,单纯强化降尿酸组1例房扑。
关键数值与推荐
- 入组条件为痛风患者且至少一处确诊的常规X线足部骨侵蚀。
- 强化降尿酸治疗目标为随机时血清尿酸≤5 mg/dL(300 µmol/L)并持续整个研究期间。
- 地舒单抗剂量为60 mg皮下注射每6个月一次。
- 主要结局评估时间点为基线至12个月。
临床怎么用
- 对于已接受强化降尿酸治疗的痛风骨侵蚀患者,加用地舒单抗不应以改善骨侵蚀CT评分为目的。
- 地舒单抗虽显著降低血清CTX,但未转化为12个月CT骨侵蚀评分的改善。
局限性
- 本研究为先导试验,样本量仅20例。
- 研究为开放标签设计。
- 随访时间为12个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion. We sought to determine if the addition of denosumab (a monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand - RANKL) to intensive urate-lowering therapy (ULT) improves gouty bone erosion. METHODS: Open-label, parallel-group pilot randomized controlled trial in which 20 participants with gout with at least one confirmed conventional radiographic foot bone erosion were assigned in a 1:1 allocation to receive denosumab (60 mg subcutaneous every 6 months) added to intensive ULT (serum urate ≤5 mg/dL or 300 µmol/L at the time of randomization and continued for the duration of the study), or intensive ULT alone. The primary outcome was the change in the bilateral foot and ankle computed tomography (CT) bone erosion score from baseline to 12 months, assessed by an experienced musculoskeletal radiologist blinded to study assignment. Secondary outcomes included change in serum C-terminal telopeptide (CTX), and patient reported outcomes of pain and function. RESULTS: Although serum CTX declined markedly in the denosumab/ULT group compared with the ULT alone group, there was no interval change in CT erosion score in either the denosumab/ULT or ULT alone group after one year of follow-up. Other secondary outcomes did not differ between groups. There were two severe adverse events: One patient developed atrial fibrillation (on denosumab/ULT) and another atrial flutter (on ULT alone). CONCLUSIONS: In this pilot study, denosumab did not offer additional benefit to intensive urate lowering therapy for gouty bone erosion.
引用
- Gaffo AL, Saag K, Doyle AJ, et al. Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial. Semin Arthritis Rheum. 2021. PMID: 34706311. doi:10.1016/j.semarthrit.2021.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。